(2E)-1-(4-methoxyphenyl)-3-(thiophen-2-yl)prop-2-en-1-one, 95.0%, 2g

2-Methyl-1-phenyl-1h-1,3-benzodiazole, 98%, 100mg

4-(3,5-difluorobenzoyl)-8-methyl-1-oxa-4-azaspiro[4.5]decane-3-carboxylic acid, 95.0%, 1g

3-(2,6-dimethylphenyl)-3',4',5'-trifluoropropiophenone, 97.0%, 1g

7-BROMOBENZOFURAN-3-CARBOXYLIC ACID, 95.0%, 250mg

tert-Butyl 3-propoxypyrrolidine-1-carboxylate, 97.0%, 250mg

(3,5-Di-tert-butyl-4-hydroxyphenyl)boronic acid, 97.0%, 1g

5-Bromonaphthalen-1-ol, 95.0%, 100mg

(2S,2'S)-2,2'-(1,3,6,8-Tetraoxobenzo[lmn][3,8]phenanthroline-2,7(1H,3H,6H,8H)-diyl)dipropanoic acid, 98%, 5g

2-Iodoquinoline, 95.0%, 1g

6-BROMO-1-(SEC-BUTYL)-3-METHYL-1H-INDOLE-4-CARBOXYLIC ACID, 95.0%, 250mg

Phase contrast slide set with 20x and S100x PLPHi IOS infinity corrected objectives and phase contrast rings for 20x/S100x

5-(4'-Methyl-[1,1'-biphenyl]-2-yl)-1-trityl-1H-tetrazole, 97%, 5g